Migraine is a common headache disorder and constitutes a significant source of distress from both a personal and societal perspective. Treatment options are limited.

Recent evidence points to metabolic changes in the brain as possible causes of migraine, via reduced available energy or a spiking need for it, resulting in a relative insufficiency.

Galcanezumab (Emgality) is a monoclonal antibody, which targets CGRP, given in a monthly injection for the prevention of migraines.

While galcanezumab is unlikely to provide monotherapy for migraines, it is a novel therapy that may be added for cases of severe or frequent migraines.